Clinical Neuroscience Division, National Center for PTSD
West Haven, Connecticut, 06516, United States
NCT Number: NCT02019940
This open label study will evaluate the safety and efficacy of riluzole in patients with PTSD. Patients will receive riluzole 50mg twice per day orally for 12 weeks as outpatient, with a one month follow up at week 16.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Phase 1
West Haven, Connecticut, 06516, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Change from baseline to 12 weeks
The CAPS is a standardized clinician-rated instrument to assess the presence and severity of PTSD symptoms. The scores range from 0 (minimum) to 80 (mazimum). Higher scores reflect worse symptoms.
Time frame: 12 weeks
Time frame: 12 weeks
Time frame: 12 weeks
Time frame: 12 weeks
Yale University
Other
An Investigation of the Effects of Riluzole in Patients With Post-Traumatic Stress Disorder (PTSD)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06403449
Mental Disorders, PTSD
Linxia, Gansu, China
View Trial DetailsNCT04523922
Alcohol Use Disorder, Alcohol-Related Disorders
Charleston, South Carolina, United States
View Trial DetailsNCT06868446
Mental Disorders, PTSD
Tallahassee, Florida, United States
View Trial DetailsNCT03778307
Endothelial Dysfunction, Mental Disorders
Los Angeles, California, United States
View Trial Details